A patient with chronic renal failure who experienced symptomatic ventricular tachycardia was treated successfully with procainamide (PA) after numerous dosage adjustments to optimize his clinical response and serum PA and NAPA concentrations. Efforts to maintain total combined serum levels at 20–30 μg/ml led to sustained ventricular ectopy whenever the serum PA levels decreased to < 8 μg/ml.
WhitingRB. Ventricular premature contractions: Which should be treated?. Arch Intern Med1980; 140: 1423–6.
2.
WarnowizMADenesP. Chronic ventricular arrhythmias: Comparative drug effectiveness and toxicity. Prog Cardiovasc Dis1980; 23: 225–36.
3.
GreenspanAMHorowitzLNSpielmanSRJosephsonME. Large dose procainamide therapy for ventricular tachyarrhythmia. Am J Cardiol1980; 46: 453–62.
4.
GivsonTPMatusikEJBriggsWA. N-acetylprocainamide levels in patients with end-stage renal failure. Clin Pharmacol Ther1976; 19: 206–12.
5.
LimaJJ. Procainamide. In: EvansWESchentagJJJuskoWJ, eds. Applied pharmacokinetics: Principles of therapeutic drug monitoring. San Francisco: Applied Therapeutics, Inc., 1980: 404–35.
6.
LimaJJGoldfarbALContiDRSafety and efficacy of procainamide infusions. Am J Cardiol1979; 43: 98–105.
7.
RodenDMReeleSBHigginsSBAntiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: Comparison with procainamide. Am J Cardiol1980; 46: 463–8.
8.
WinkleRAJailsonPKatesREPetersF. Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide. Am J Cardiol1981; 47: 123–30.
9.
KlugerJLeechSReidenbergMMLloydVDrayerDE. Long term antiarrhythmic therapy with acetylprocainamide. Am J Cardiol1981; 48: 1124–32.
10.
GiardineEVFensterPEBiggerTJMayersohnMPerrierDMarcusFI. Efficacy, plasma concentrations, and adverse effects of a new sustained release procainamide preparation. Am J Cardiol1980; 46: 855–62.
